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Abstract
Hsp60 is an abundant and highly conserved family of intracellular molecules. Increased levels of this family of proteins have
been observed in the extracellular compartment in chronic inflammation. Administration of M. leprae Hsp65 [WT] in
[NZBxNZW]F1 mice accelerates the Systemic Lupus Erythematosus [SLE] progression whereas the point mutated K
409A
Hsp65 protein delays the disease. Here, the biological effects of M. leprae Hsp65 Leader pep and K
409A pep synthetic
peptides, which cover residues 352–371, are presented. Peptides had immunomodulatory effects similar to that observed
with their respective proteins on survival and the combined administration of K
409A+Leader pep or K
409A pep+WT showed
that the mutant forms were able to inhibit the deleterious effect of WT on mortality, indicating the neutralizing potential of
the mutant molecules in SLE progression. Molecular modeling showed that replacing Lysine by Alanine affects the
electrostatic potential of the 352–371 region. The number of interactions observed for WT is much higher than for Hsp65
K
409A and mouse Hsp60. The immunomodulatory effects of the point-mutated protein and peptide occurred regardless of
the catalytic activity. These findings may be related to the lack of effect on survival when F1 mice were inoculated with
Hsp60 or K
409A pep. Our findings indicate the use of point-mutated Hsp65 molecules, such as the K
409A protein and its
corresponding peptide, that may minimize or delay the onset of SLE, representing a new approach to the treatment of
autoimmune diseases.
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Introduction
Heat shock proteins [Hsp] are among the most conserved
molecules found in prokaryotes and eukaryotes. Intracellular Hsp
molecules participate in fundamental cellular processes by acting
as chaperones or chaperonins [1,2]. Under steady state conditions,
Hsp molecules represent about 5% of the total intracellular
proteins. Under stress conditions this rate may rise significantly
[almost 5 times] [3]. The induction of Hsp expression is tightly
regulated, as over-expression of this protein may persistent
adversely affect the intracellular homeostasis and may lead to cell
death [4].
Despite its main function as a chaperone, the participation of
the 60 kDa heat shock protein [Hsp60] in chronic-inflammatory
processes, including autoimmune diseases, has been widely
documented [3,5,6]. Heat shock proteins and their derived
peptides have been shown to be involved in the pathogenesis of
autoimmune diseases such as arthritis, diabetes, and intestinal
inflammation as well as encephalomyelitis [reviewed in [6]]. It is
believed that the Hsp molecules found in the extracellular
compartment play a role in the evolution of autoimmune diseases
[7,8]. In addition, inflammation can significantly increase
endogenous Hsp levels, which affect the exposure of cryptic
epitopes during antigen presentation and activates an immune
response [9].
The fact that in pathophysiological conditions antibodies and T
cells may react with self Hsp60 or bacterial Hsp65 suggests that
these two proteins are capable of triggering cellular reactions in
autoimmune diseases, because the similarity of the bacterial
protein and the self antigen [6,10]. Moreover, increased levels of
anti-Hsp60 and anti-Hsp65 antibodies are not restricted to
pathological conditions, being also found in healthy individuals
[11,12]. Response to proteins or any peptides should be a naturally
occurring subliminal immune phenomenon that participates in the
maintenance of neutralization and equilibrium in ordered states
aimed to this class of endogenous molecules [13]. Based on the
concept of molecular mimicry and on reports suggesting distinct
physiological roles for self Hsp60 and bacterial Hsp65 molecules, it
has been suggested that variable humoral responses to these
proteins may correlate with the occurrence of chronic-degenera-
tive and autoimmune processes [14].
Previously, it has been shown that by adding Hsp to any host an
imbalance is observed in both the physiological and the
immunological systems. Thus, it was hypothesized that the passive
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24093administration of wild type [WT] M. leprae Hsp65 interferes with
the body endogenous equilibrium by enhancing the entropy of the
immunobiological system. Indeed, in a previous study we observed
that the severity of Experimental Autoimmune Uveitis [EAU] [15]
and the Systemic Lupus Erythematosus [SLE] [16] were increased
in mice models that had the wild type M. leprae Hsp65 passively
administrated. In contrast, the administration of the K
409A Hsp65,
a point-mutated molecule [17], did not affect SLE evolution or
survival; the combined administration of WT and K
409A Hsp65
proteins showed that the K
409A is able to inhibit but not reverse
the effects of WT on F1 mice. These data suggest that Hsp65 has a
central role in SLE progression, and that the K
409A may mitigate
and delay the development of SLE.
The point mutation of K
409A M. leprae Hsp65 is located at the
catalytic site. Thus, it was asked whether disease severity is an
effect unrelated to the catalytic function of the WT molecule and
whether this same region in either K
409A or WT Hsp65 molecules
play a role on the immunobiological effects associated to mice. To
investigate this issue, it was synthesized two peptides that cover
residues 352–371 of the M. leprae Hsp65 WT peptide [here called
Leader pep] and its mutated form [here called K
409A pep]. It was
then observed how each of these peptides impacted the
development and progression of SLE in murines. It was found
that the immunomodulatory effects caused by each peptide were
similar to that caused by their corresponding proteins and that the
observed effect occurred regardless of the catalytic activity.
Results
Determination of primary structure, synthesis, and
characterization of peptides
We have previously shown that administration of M. leprae
Hsp65 in [NZBxNZW]F1 animals accelerated disease progression
whereas the point-mutated K
409A Hsp65 protein had opposite
effects in the survival of F1 mice [16]. Since mutation was
performed at the hypothetical catalytic site [17], we wanted to rule
out the possibility that the enzymatic activity of the WT molecule
was contributing to disease severity. For this, two synthetic
peptides, corresponding to the 352–371 region of the WT and
mutant Hsp65 molecules, named here as Leader pep and K
409A
pep respectively, were designed. These molecules comprise only
part of the amino acid sequence of the putative catalytic site; in
addition, the 352–371 Leader peptide cannot display any catalytic
activity because it lacks the minimal structure necessary for an
enzyme. Panel A in Figure 1 shows the analytical profile of the
K
409A pep purification after HPLC reverse-phase chromatogra-
phy. The molecular mass of the K
409A and Leader peptides
corresponded to m/z 2,323.26 and m/z 2,380.54, respectively
[Figure 1, panel B]. Panel C [Figure 1] shows the amino acid
sequence of the Leader pep and K
409A pep.
Immunomodulatory effects of synthetic peptides are
similar to those of their respective proteins
[NZBxNZW]F1 mice of 45 day-old were inoculated with
Leader or K
409A pep and observed for 315 days [which
correspond to the maximal survival time of the non-treated mice-
control group] or for shorter periods if death occurred earlier than
315 days. Survival of the Leader pep-inoculated animals was
significantly affected [p,0.01] with approximately 45% [9 out of
15] of mice dying at 53 days of age and showing a mean survival
time [MST] of 58 days, as compared to non-treated mice
[Figure 2, panel A - MST=267635]; 60% [3 out of 5] of the F1
mice inoculated with the K
409A pep survived beyond the age of
315 days. Therefore, estimated survival time of these animals [263
day-old] was limited to the largest censored time, being
significantly higher than the Leader pep-inoculated mice
[p,0.05]. No significant differences were observed between
K
409A pep and control mice, but it is worth mentioning that no
animal in the control group reached the age of 315 days. Thus, the
inoculation with K
409A pep may have increased the survival time
of these mice. Moreover, peptide treatment generated similar
effects on survival of F1 mice when compared to their respective
WT and mutant Hsp65 proteins. There were no significant
differences in response to DNA [titers approximately 7.5log2] and
to Hsp65 IgG isotypes [titers approximately 4log2] in both
experimental groups 7 days after the peptides were inoculated.
Treatment with mouse Hsp60 has no effect on SLE
progression
It is hypothesized that the presence of the Hsp60 in the
extracellular compartment can propagate the inflammatory
response, thereby aggravating autoimmune diseases [6,18]. In
order to evaluate if the mouse Hsp60 has a similar effect to that
observed with Hsp65 of M. leprae in disease severity, the autologous
Hsp60 protein was injected in F1 mice. Sequence alignment of the
region corresponding to the synthetic peptide M. leprae Hsp65 and
mouse Hsp60 proteins revealed 55% of sequence identity and the
presence of seven amino acids highly conserved [Figure 2, panel
B]. No difference in survival times was observed between these
groups [Figure 2, panel C].
Anti-Hsp65 isotype production in HIII mice
To evaluate whether Hsp65 synthetic peptides – Leader and
Mutant – were immunogenic, HIII mice were immunized and the
anti-Hsp65 antibody levels at different time-points determined.
Basal specific IgG1 antibody levels were observed in all
experimental groups [Figure 3, panel A]. IgG2a antibody titers
increased in both groups, starting with 4.5log2 on day 14 and
reaching ,8log2 on day 25 post-immunization [Figure 3, panel B].
These data suggest that Hsp65 peptides are immunogenic even
under non-inflammatory conditions, but not pathogenic since HIII
mice did not develop any apparent illness. Notably, immunization
of HIII mice with WT M. leprae Hsp65, emulsified in IFA, does not
induce specific antibody titers [16].
The inoculation of K
409A molecule and anti-K
409A
antibodies against Hsp65 mitigates SLE progression
In order to investigate if K
409A molecules – protein and peptide
forms –neutralize the effect of the wild type Hsp65 protein or of
the Leader peptide, F1 female mice aging forty-five days received
K
409A pep or K
409A protein and 7 days later were inoculated with
the WT molecule or the Leader pep [K
409A pep+WT or
K
409A+Leader pep groups, respectively]. Survival of the groups
that received prior inoculation of mutant peptide or protein forms
was significantly enhanced [K
409A pep+WT group: 271637 days,
and K
409A+Leader pep group: 289654 days, p,0.001] when
compared to groups previously administrated with WT
[WT+K
409A group] or to those that received the Leader pep
only. These latter groups showed an MST of 105610 and 5364
days, respectively [Figure 4, panels A and B]. The WT+K
409A pep
group was not included in this study because the K
409A is able to
inhibit but not reverse the effect of prior inoculation of rHsp65WT
protein on the [NZBxNZW]F1 mouse mortality [16].
To further investigate whether anti-K
409A antibodies inhibit the
effect of Leader peptide in SLE, F1 animals were inoculated with
anti-K
409A serum produced in HIII mice and adsorbed with the
Leader pep or normal mouse serum [NMS]. Treatment with anti-
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409A pep synthetic peptide. A) Purification of K
409A pep synthetic peptide by reversed-phase chromatography.
B) Mass spectrometry analysis of pure K
409A pep; mz 2,323.26. C) Amino acid sequence of Leader pep and K
409A pep synthetic peptides.
doi:10.1371/journal.pone.0024093.g001
Figure 2. Effect of the Leader pep and K
409A pep peptides and autologous Hsp60 inoculation on SLE. A) Survival of [NZBxNZW]F1
female mice [n=5 to 15/group] inoculated with synthetic peptides at 45 day-old. 1Estimate was limited to the largest censored time [315 day-old].
#Data from [16]. MST=Mean survival time. *p,0.05: K
409A pep versus Leader pep; **p,0.01: Leader pep versus control group; ***p,0.001: WT versus
control group. Results are representative of 2 independent experiments. B) Amino acid alignment of M. leprae Hsp65 and mouse Hsp60. Amino acid
homology colors: Identical: red; strongly similar: green; different: black. C) Survival of [NZBxNZW]F1 45-day-old female mice [n=5 to 6] inoculated
with mouse Hsp60 [¤]; control group [D]. Results are representative of 2 independent experiments.
doi:10.1371/journal.pone.0024093.g002
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24093Figure 3. Anti-Hsp65 antibody production in HIII mice. Time-course production of anti-Hsp65 IgG1 [A] and IgG2a [B] antibodies in HIII mice
[n=3 to 5/group] immunized with Leader pep or K
409A pep. Antibody titers were evaluated at 7, 14, and 25 days after immunization with synthetic
peptides. Results are representative of 2 independent experiments. Dashed lines represent basal levels. Data are expressed as means 6 SD.
doi:10.1371/journal.pone.0024093.g003
Figure 4. The neutralizing potential of previous inoculation of K
409A molecule and anti-K
409A antibodies on SLE suppression. A)
Combined effect of K
409A and WT in survival time. Forty-five-day-old female [NZBxNZW]F1 mice [n=4 to 6/group] were inoculated with K
409A pep or
K
409A, and after 7 days received WT rHsp65 [K
409A pep+WT group: &] or Leader pep [K
409A+Leader pep group: e].
#Data from [16]. ***p,0.001:
K
409A pep+WT and K
409A+Leader pep versus WT+K
409A group. B) Survival analysis of [NZBxNZW]F1 45-day-old mice [n=4 to 7/group] inoculated with
Leader pep [N]; Leader pep incubated with HIII normal mice sera [#]; or Leader pep incubated with HIII K
409A-immunized mice [.]. Leader pep group
was the reference group for unpaired t-test analysis; **p,0.01. Results are representative of 2 independent experiments.
doi:10.1371/journal.pone.0024093.g004
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409A adsorbed serum resulted in prolonged survival of mice
previously inoculated with Leader pep, as compared to controls
[Figure 4, panel B], suggesting that anti-K
409A antibodies
neutralize the deleterious effect of the Leader pep.
Replacement of Lysine for Alanine at position 362 affects
the electrostatic potential and interactions in M. leprae
Hsp65
In order to better understand the effects of Hsp65 WT and
K
409A protein- treatment in F1 mice, structural models of both
molecules were built. WT M. leprae Hsp65 and mutant were built
based on the structural coordinates from M. tuberculosis Hsp65
[PDB code 1SJP_A] [19], which shows 97.7% of identity with the
M. leprae Hsp65. The stereochemical quality of the models was
evaluated with Procheck and the Ramachandran plot revealed
94.5% and 96% of residues in most favored regions for WT Hsp65
and mutant, respectively. No residues were found in generously
allowed or disallowed regions in both models [data not shown].
For comparison, the mouse Hsp60 was also modeled using the
structural coordinates of the chaperonin GroEL from E. coli [PDB
code 1SX3] [20], which has 50% of amino acid sequence identity.
Ramachandran plot for this model showed 94.8% of residues in
most favored regions and none in generously or disallowed regions
[data not shown]. All the models presented the three characteristic
apical, intermediate, and equatorial domains found in E. coli
Hsp60 [Figure 5, panel A, colored in yellow, magenta, and green,
respectively] [21]. The peptide region is located in the apical
domain [colored in orange and red], forming a ‘‘handle’’ that is
very exposed and which does not interact with the ATP ligand-
binding site in the equatorial domain [shown in red spheres]. In
addition, based on the rigid model data, the substitution of Lys 362
by Ala does not modify the alpha helix arrangement in the 352–371
region. The structural superposition of the three proteins revealed
no significant differences, measured by the root mean square
deviation [r.m.s.d.] for the a ´-carbon. Values varied from 0.4 A ˚
[WT versus K
409A] to 1.1 A ˚ [WT/K
409A versus mouse Hsp60]
[Figure 5, inset table]. On the other hand, there are significant
changes in the polar contacts and electrostatic potential of the
peptide region, when compared among the three proteins. The
position of the fragment covering residues 352 to 371 in the WT
Hsp65 protein allows more inter alpha-helices M and J
interactions [Figure 5, panel B and Table 1], than the same
fragment in the Hsp65 K
409A and mouse Hsp60 [Figure 5, panels
C and D, respectively, and Table 1]. According to this model, in
the WT Hsp65, residues Y358, E361, K362, E365, and R366, [all
of them located in the M helix in the 352–371 peptide region]
compose eight contacts connecting helices J and L, including two
contacts performed by the Lysine 362 [K362/NZ – D281/OD2,
2.8 A ˚ and K362/NZ – Y358/OH, 2.9 A ˚; Table 1]. When Lysine
is replaced by Alanine [K
409A mutant], only the R413, equivalent
to the R366 in the WT Hsp65, has contacts with D336 of the L
helix and E397 [J helix].
A slight increasing of the electrostatic potential is observed when
the 352–371 fragment of both WT and mutant molecules are
compared [Figure 5, panels B and C]. This may have some effect
on the folding and structure of the M. leprae Hsp65. Curiously,
although the mouse Hsp60 conserves the Lysine at the same
position found in WT Hsp65, the number of interactions of the
peptide region in this protein follows the profile of K
409A mutant
Hsp and is similarly decreased [Figure 5, panel D and Table 1].
The amino acid hydropathicity and polarity of the peptide region
in the three proteins was compared using Protscale server [22],
according to [23] and [24], respectively. WT Hsp65 and K
409A
showed similar profiles for polarity but an increased hydropathi-
city in Hsp65 K
409A, which is comparable to that calculated for
mouse Hsp60, was observed. In addition, mouse Hsp60, which
shares only 55% of sequence identity with WT Hsp65, presented
high polarity in the first eight residues of the 379–398 fragment
[data not shown].
Distinct potential binding of the 352–371 amino acid
regions of WT and K
409A proteins to MHC class I and II
Theoretical analysis evidenced that for the MHC class I only 1
out of 10 alleles of the H-2 molecule available for the RankPep
recognizes the 352–371 region of WT and K
409A. The recognition
ratio with the consensus sequences of each molecule of MHC class I
was about 45% for both proteins [Figure 6 – panel A and B].
However, distinct class I molecules were predicted to bind to the
352–371 amino acid region of the Hsp65 wild-type and mutant
molecules: the H-2
kd allele recognized the SDYDREKL peptide-
epitope of WT [Figure 6 – panel A] and the H-2
kb allele recognized
the ALQERLAKL of the mutant protein [Figure 6 – panel B]. For
theMHCclass II, 12and 17 potentialMHC peptide-binders toWT
and K
409A molecules were respectively identified. There are 12 H-2
alleles and 49 HLA sub-alleles available at RankPep. While, the
wild type and mutant proteins share these same alleles for class II,
five additional HLA alleles that recognized the 352–371 region of
K
409A exist [Figure 6 – panel D].
Discussion
Motivated by the opposite immunomodulatory effects of WT
and K
409A Hsp65 on SLE, we analyzed the synthetic peptides
corresponding to the region of the K
409A mutation in
[NZBxNZW]F1 mice, a model of spontaneous Systemic Lupus
Erythematosus. Following our previously concepted system based
on the addition of Hsp to imbalance the endogenous equilibrium
of the immunobiological system [16], the Leader and K
409A
peptides were passively administered to these F1 mice. Here the
primary sequence of synthetic peptides derived from M. leprae
Hsp65 and their effects in this model are presented. The present
data showed that, in general, the action of these synthetic peptides
resembled that of their respective proteins, indicating that the
residues 352–371 of both M. leprae Hsp65 and of the mutated form
K
409A are the ones responsible for the effects on mice survival.
This rules out the hypothesis that the immunomodulatory effect
previously observed [16] was associated with a catalytic activity of
the M. leprae Hsp65. Furthermore, the effect of each peptide was
comparable to that observed in its corresponding proteins. Not
only that but this effect was also amplified. In other words, there is
a reduction in the survival time of mice injected with the Leader
pep, and a tendency for increased survival time with K
409A pep
inoculation, as compared to the survival times observed with the
two corresponding proteins. Although there were no significant
differences in survival times between K
409A pep and the control
group, a lower standard deviation in K
409A pep-inoculated
animals was observed, suggesting that this peptide could increase
the survival of animals that would otherwise have an early death,
possibly being the ones with more severe disease. Similar
observations have been made previously in lupus animals
inoculated with the K
409A Hsp65 protein [16].
Because the administration of K
409A protein as well as K
409A
pep had no effect on mortality of [NZBxNZW]F1 and the K
409A
protein presents higher immunogenicity than the WT Hsp65 [16],
the effects of the co-administration of K
409A+Leader pep or K
409A
pep+WT on the survival of F1 animals were evaluated. The
survival times of K
409A+Leader pep and K
409A pep+WT animals
were significantly higher when compared to Leader pep or WT-
M. leprae Hsp65 Peptides in Murine Lupus
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409A protein
and its corresponding synthetic peptide are able to inhibit the
deleterious effect of the Leader pep or WT on the mortality of the
[NZBxNZW]F1 mouse. Indeed, the transfer of the anti-K
409A
serum produced in HIII mice and adsorbed with the Leader pep
reinforces the mitigating effects of K
409A forms in SLE.
Altogether, these data indicate the neutralizing potential of prior
inoculation of K
409A molecule, both protein and its peptide, and
anti-K
409A antibodies against Hsp65, and possibly against
autologous Hsp60. Further protein–protein interaction studies
will expand our knowledge on the potential therapeutic applica-
tion of K
409A forms on lupus disease, and possibly on other
chronic degenerative autoimmune processes.
Despite the various pro-inflammatory properties described for
Hsp60 family members [25,26,27,28], other reports support an
immune regulatory role for self Hsp60 [29,30,31,32,33]. Here, the
administration of autologous Hsp60 protein did not change
survival of F1 animals. Thus, it is possible that in this model the
recombinant Hsp60 does not activate immune cells; otherwise the
molecule would be recognized as a self-antigen. However, it is
possible that administration of higher doses of autologous Hsp60
[.2.5 mg] interferes with lupus progression.
The sequence alignment analysis of 352–371 amino acids of M.
leprae Hsp65 and the corresponding 379–398 of mouse Hsp60
shows 55% of identity and an additional of 30% of strongly
conserved amino acids. The literature shows that the amino acid
Figure 5. Structural modeling of M. leprae WT and K
409A Hsp65 and mouse Hsp60. A) Superposition of the WT and K
409A M. leprae Hsp65
overall structures showing the three characteristic domains: apical [yellow], intermediate [red], and equatorial [green], with the ADP evidenced in
spheres. The peptide region [352 to 371 residues in WT Hsp65] is evidenced in orange and regions with high B-factor described by [21] are shown in
red. The inset table shows the results of the structural alignment of the proteins. B, C, and D) Main differences in the polar contacts performed by the
peptide region and that affect the electrostatic potential in the WT Hsp65, Hsp65 K
409A, and mouse Hsp60 proteins, respectively. Red color shows
negative and blue positive charges.
doi:10.1371/journal.pone.0024093.g005
Table 1. Polar contacts identified in the three models built for WT Hsp65, Hsp65 K
409A, and mouse Hsp60.
WT Hsp65 Hsp65 K
409A mouse Hsp60
residue 1 residue 2 distance (A) residue 1 residue 2 distance (A) residue 1 residue 2 distance (A)
R343/NZ D289/OD1 2.7 E397/OE1 R413/NH1 2.7 R393/NH1 D315/OD2 2.8
E350/OE2 R366/NH2 2.8 D336/OD2 R413/NH2 2.7 K389/NZ Y385/OH 3.1
E350/OE2 R366/NH1 2.7 R390/NH1 Q335/OE1 2.8
R282/NH1 E365/OE2 2.8
R282/NH2 E365/OE2 2.8
R282/NH1 E361/OE2 3.0
K362/NZ D281/OD2 2.8
K362/NZ Y358/OH 2.9
The region showed refers to the residues 352 to 371, according to the number of residues of the WT Hsp65 protein. Contacts in bold are those performed by K362 in WT
Hsp65 and K389 in mouse Hsp60.
doi:10.1371/journal.pone.0024093.t001
M. leprae Hsp65 Peptides in Murine Lupus
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less conserved regions of these molecules, which are recognized by
vertebrate T cells [34]. Taken together, these observations
reinforce the idea of a higher immunogenic property of M. leprae
Hsp65 as compared to that of autologous Hsp60 in disease
aggravation. They also suggest a lack of cross-reactivity of
conserved epitopes corresponding to the synthetic peptide between
mycobacterial Hsp65 and mouse Hsp60. This finding supports the
view that the structural similarity of the epitopes, based on the
anchor residues, is more important than the homology of the
primary sequence.
Several crystal structures of GroEL – E. coli Hsp60 chaperonin 1
[cpn60-1] and from other organisms are available and two of them
show GroEL in its 14-meric structure [21,35]. For the mycobac-
terial Hsp65, the crystal structure of Hsp65 M. tuberculosis reveals
its dimeric state and suggests that the concentration of Hsp65
found in the extracellular milieu is extremely low for oligomer
formation [19,36]. Also, the differences in the primary sequence of
the two chaperonins [cpn60] homologs of M. leprae – cpn60-1
[Hsp60] and cpn60-2 [Hsp65] – may contribute to the divergent
structural and functional properties observed in the Hsp60 family
members.
Here, the tertiary structure of M. leprae Hsp65 and its mutant
K
409A were based on templates of crystal monomer structure of
the M. tuberculosis Hsp65 [PDB code 1SJP] [19] and of the
chaperonin complex from Thermus thermophilus [PDB code 1WE3]
[37]. No significant changes in the tertiary structure of both
proteins, including the predicted alpha-helix where the mutated
Lysine K
409A is located, were observed. However, although the
WT and mutant Hsp65 are expressed as rigid structures based on
a model that fixes the positions of amino acids, replacing Lysine
362 by Alanine affects the electrostatic potential of the region and
the potential interactions performed by Lysine 362 and the
residues located around it. Importantly, the mutation at the 352–
371 region probably does not affect the molecular stability,
regardless whether it is in its heptamer or monomer structures,
because this region is distantly located from the ATP binding site.
In addition, the number of interactions observed at this site of the
WT Hsp65 is highly decreased when compared to mouse Hsp60
and Hsp65 K
409A; both these proteins showed a similar
hydrophobic profile for the equivalent 352–371 region of Hsp65.
These features could be related to the lack of effect and
enhancement of survival of F1 mice when they were inoculated
with autologous Hsp60 or K
409A pep, respectively. As mentioned,
because the models are shown as rigid structures, it is possible that
the differences in the peptide region affect the positions and
interactions between M and J helices. Interestingly, one of the
regions evidenced by [21] that shows the high B-factor of the
predicted protein structures, and is located exactly in the most
exposed area of the peptide region [Figure 5, panel A], is related to
a loss of interactions between the helices that are associated to the
higher mobility of the apical region. This could lead to drastic
effects on the 352–371 peptide region and protein of the K
409A
Hsp65 structure and could change the interaction with other
molecules.
The structural model shows that the 352–371 region of the
Hsp65 is exposed, and it is possible that it can be recognized by the
immune system. Our current data from immunization of HIII
mice with the Leader or K
409A peptides show that, in general, the
synthetic peptides seem to be more immunogenic when compared
to their corresponding proteins [16], especially for the wild type
protein form. This may be related to the short extension of the
peptides, which may be more easily processed and presented by
the immune system than their respective proteins. A group of small
peptides and a 20.4 kDa fragment of the C-terminal portion from
Hsp65, commonly found on the cell wall of M. leprae, are in the
cytosol of the bacillus [38]. In vitro studies also show a potential
autolysis of M. leprae Hsp65 by releasing portions of its N- and C-
terminal regions, suggesting that the antigen presentation occurs
independently of the proteasoma [39]. The process of chaperone/
Figure 6. Analysis of the prediction of peptide-epitope binding to MHC class I and II molecules for WT and K
409A M. leprae Hsp65,
focusing in 352–370 amino acid region. Theoretical amino acid sequence identification of peptide-epitopes of the WT (A) and K
409A (B) Hsp65
and the homology percentage of consensus peptide binders to MHC H2 alleles. Primary structure identification of peptide-epitopes of the WT (C) and
K
409A (D) binding to mice and human MHC class II molecules.
doi:10.1371/journal.pone.0024093.g006
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and it is believed that self-degradation is a modulation process
[39]. Therefore, the inflammation observed in chronic inflamma-
tory processes, including autoimmune diseases, may change the
conformation, the antigen processing, or self-degradation of the
Hsp65. This hypothesis is supported by a recent paper from [40].
Inflammation may also expose or more efficiently release new
determinants/epitopes, or certain epitopes such as the cryptic ones
[18], and possibly the region that comprises the 352–371 peptide.
Discrimination between the pathological and regulatory Hsp60
actions in autoimmunity is still unclear, even whether the regions
of the Hsp60 may determine their opposing immunologial
function. However, some reports suggest that different regions of
the Hsp60 molecules induces distinct immune response; prolifer-
ative response induced by N-terminal and intermediate Hsp60
peptides, which also induced IFN-c production; also, the IL-4
production was induced by the intermediate and C-terminal
regions [30]. It was reported that a C-terminal region of Hsp60
[354–366 amino acid] was involved in LPS binding and innate
immune activation [41]. On the other hand, the p277 peptide
from 437–460 amino acids of the human Hsp60 molecule
presented immunoregulatory effect in non-obese diabetic NOD
mice, by inducing IL-4 and IL-10 production [42,43].
Although there were no significant differences in the production
of anti-DNA and anti-Hsp65 IgG isotypes it is possible that these
antibodies differ in their binding affinity, leading to distinctive
potential pathogenic involvements. In the present model, a
preliminary analysis indicates that in mice receiving WT or
K
409A proteins, the avidity was ten times higher than their
respective peptides and controls at 80-day-old mice [data not
shown].
The exact pathophysiology mechanism behind the phenome-
non evoked by the K
409A has not been identified. Preliminary
results showed that the K
409A-inoculated lupus mice presented
lower number of lymphocytes in spleen when compared to WT
mice group and controls and that this effect is not mediated by
direct induction of apoptosis evaluated in vitro at 2 and 24 hours.
Furthermore, total spleen cells treated with K
409A protein or its
peptide indicate that these mutant forms did not affect in vitro cell
proliferation assay. Thus, it can be suggested that modulation
rather than activation is what occurs in the immune system. In
addition, no differences in frequency of ex vivo CD4
+CD25
+ and
CD4
+CD122
+ populations were observed. Neither difference was
observed in IL-2 cytokine production in splenic cells in WT and
mutant groups when compared to controls. Also, no differences in
splenic IL-10 levels were observed [unpublished data]. It is
possible that, at least in part, the immunomodulatory effect of the
K
409A protein/peptide is explained by a balanced production of
IgG1 and IgG2a anti-DNA along the life and high levels of
humoral IFN-c in this experimental group when compared to WT
and control groups [16]. In a systemic and multifactorial chronic
disease such as SLE, it must be considered that there is not a
unique explanation and assertion, since competing and overlap-
ping mechanisms occur in different compartments and at the same
time.
The discordant results obtained in vivo with WT and K
409A
forms raise some questions, considering that the protein and the
peptide are point-mutated molecules. The analyses of RANKPEP
prediction of peptide-epitope of WT and K
409A Hsp65 were
relatively distinct in their potential to bind to MHC molecules.
Therefore, it can be hypothesized that the MHC Hsp65-binding
potential is one of the features responsible, at least in part, for the
effects that Hsp65 causes in the survival of F1 mice. Because the
concomitant administration of the K
409A pep and Leader pep in
lupus mice had a predominant effect of the mutant peptide, we
assume that they compete for the same target on molecular and
cellular levels, such as antigen presenting cells and MHC
molecules. This hypothesis deserves further investigation.
As shown in our studies, a single base change in the DNA can
have remarkable effects, such as those artificial changed molecules
observed for the altered peptide ligands [APL]. There are reports
in the literature of natural variants or mutations of M. leprae Hsp65
[44]. Additionally, amplification of some regions of the M. leprae
Hsp65 may be used for a differential diagnosis of leprosy [45].
Nevertheless, the molecular and cellular mechanisms caused by
these variations in the M. leprae Hsp65 in infected individuals
remain unknown.
Our findings suggest that the use of point-mutated molecules,
such as the K
409A protein and its corresponding peptide, may
minimize or delay the onset of SLE, representing a new possibility
of treatment for this and other autoimmune diseases.
Evolutionarily, adaptations towards the functional aspects of the
proteins might have been initially predominant and, along eras,
associated to the progressive organism complexity, as structural
diversities were fixed. Distinct functions, binding motifs, and
molecular interactions are reflected in conserved families, such as
those of the immunoglobulins or of the heat shock proteins. Thus,
the molecular evolution would be defined by the capacity of the
combination potential between molecules, their affinity, and
molecular conformation in the lato sense. Relative to energy
dissipation, it can be assumed that during the evolutionary process,
the best intermolecular adjustment determines species survival.
The molecular relationships and the cellular interactions can be
understood as actions defined for balance and sequential reactions.
The dynamics of the complex network that delineates the immune
system, and also the complex toxicity processes, can be included in
the contexts of imbalance of dissipative structures and ordered
disorganization, which are guided by causal and extemporal
sequences. It must take into account that the perception of the
significance of the concept of self/non-self is limited by possibilities
of detection or not, of binding to or neo-exposition of pre-existing
molecules. To the qualitative network emergence must be
adjoined the extremely variable and complex quantitative and
pleiotropic expression of responsiveness. For most of the
physiological processes that are cumulative and irreversible
[mainly those related to the immune system] it is possible that
even though irregularities, a variety of subliminal and undetected
pathological processes could be initiating. Based on these and our
previous data, Hsp could be understood as toxins. Immunities or
toxins, behaving as a broken mirror in which similarities or
contrasts acquire variable structures and expressions along the
individual life, give surety to species survival.
Materials and Methods
Animals
Mice were caged and handled under ethical conditions,
according to international rules of animal care specified in the
International Animal Welfare Recommendations [46]. New
Zealand Black [NZB] female and New Zealand White [NZW]
male mice were obtained from the animal facilities of the
University of Sa ˜o Paulo, Brazil and from the Gonc ¸alo Moniz
Research Center, Salvador, Bahia, Brazil. The genetically selected
high responder mice [HIII line] were obtained from the
Immunogenetics Laboratory of Instituto Butantan, Sa ˜o Paulo,
Brazil. Parental lines were mated in our laboratory to produce
[NZBxNZW]F1 hybrids. After weaning, F1 mice were housed in
groups of four to six animals in plastic cages filled with hardwood
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The animals were kept in a room with controlled lighting [12-h
light/dark cycle], pressure, humidity, and temperature [24uC]. All
the procedures were approved by Institutional Animal Care
Committee at Butantan Institute [CEUAIB # 196/05].
Peptide synthesis
Leader pep [ENSDSDYDREKLQERLAKLA] of M. leprae
Hsp65 and K
409A pep [ENSDSDYDREALQERLAKLA] of the
mutated form K
409A, both covering residues 352–371, were
synthesized using the Fmoc [N-(9-fluorenyl)methoxycarbonyl)
procedure [47] in a Shimadzu PSSM-8 peptide synthesizer
[Shimadzu, Tokyo, Japan]. The Fmoc-amino acids were pur-
chased from Novabiochem [Nottingham, UK]. The synthetic
peptides were purified by preparative reversed-phase chromatog-
raphy [reversed-phase HPLC], and the purity and identity of the
peptides were confirmed by matrix-assisted laser desorption
ionization time-of-flight [MALDI-TOF] mass spectrometry on
Ettan MALDI-TOF/Pro instrument [Amersham Biosciences,
Buckinghamshire, UK] and by analytical reversed-phase high
performance liquid chromatography [HPLC] [Shimadzu Inc.,
Tokyo, Japan].
Expression of the recombinant M. leprae Hsp65 in
Escherichia coli
Expression and purification of the recombinants M. leprae WT
and K
409A Hsp65 was done as described in [16].
Animal treatment
Forty-five-day-old female [NZBxNZW]F1 mice were intraper-
itoneally [i.p.] inoculated with a single dose of 2.5 mg of Leader
pep or K
409A pep in 0.2 ml of phosphate buffer saline pH7.4
[PBS]. An additional group of animals was inoculated with 2.5 mg
of mouse Hsp60 [Stressgen, ESP-741D] in 0.2 ml of PBS. The
number of animals varied between 5 and 15 per group and control
mice received 0.2 ml of PBS. Peptide-inoculated and control mice
were periodically bled and the individual serum samples stored at
220uC until titration by ELISA of the anti–DNA and anti–Hsp65
antibodies. Animals were evaluated until 315 days of age or until
their death. Mice were periodically examined for clinical signs
including development of ascites, lethargy, anorexia, and death.
Anti-Hsp65 antibody production in High responder mice
Three- to four-month-old HIII mice were immunized subcuta-
neously with 10 mg of WT rHsp65, K
409A, Leader pep, or K
409A
pep emulsified in incomplete Freund’s adjuvant [IFA] [v/v] in a
final volume of 200 mL. These high responder mice were
genetically selected according to high responsiveness and
expressed no epitope nor isotype restrictions [48,49]. For the
recombinant Hsp65 proteins, after approximately 15 days of
immunization [primary response], animals received a subcutane-
ous booster of 10 mg of the respective recombinant proteins
emulsified in IFA [v/v] in a final volume of 200 mL. Mice were
periodically bled by retro-orbital venous plexus and the samples
collected were kept at 220uC for further analysis of individual
primary and secondary responses.
In vitro and in vivo sera assays
The in vitro and in vivo neutralizing sera assays were carried out as
follows: 2.5 mg of Leader pep were incubated for 30 minutes at
37uC with serum anti-K
409A produced in HIII mice [as described
above] or HIII normal mice serum [NMS] at 1:4 dilution.
Mixtures were centrifuged at 14000 rpm for 10 minutes at 4uC,
and the supernatants were collected and inoculated in
[NZBxNZW]F1 female mice [n=4–7/group] with 45 days of
age by the intraperitoneal route. As control, F1 mice were
inoculated with 2.5 mg of Leader pep. Clinical signs, including
ascites development, lethargy, and anorexia, as well as the mean
survival time were evaluated.
Combined administration of recombinant Hsp65 and
synthetic peptides
Forty-five-day-old female [NZBxNZW]F1 mice were inoculated
i.p. with a single dose of 2.5 mgo fK
409A pep or K
409A protein in
0.2 ml of PBS. Seven days later, animals received 2.5 mgo fW T
rHsp65 or Leader pep, i.p. Mice were periodically bled; individual
serum sample titration and clinical signs were evaluated as
described above.
Titration of anti-DNA and anti-Hsp65 antibodies
Specific IgG1 and IgG2a isotypes were detected with indirect
ELISA as described in [16].
Molecular modelling of the tridimensional structures of
M. leprae Hsp65 and mouse Hsp60
The structural models of M. leprae WT and K
409A mutant Hsp65
and mouse Hsp60 were generated using the Modeller 9v2 program
[50], driven by satisfaction of spatial restraints, using the protein
sequences P09239 and P63038, respectively. Search for best models
were performed using FUGUE [51] and PSI-Blast against Protein
Data Bank as a search set. The mouse Hsp60 tridimensional model
was generated based on the atomic coordinates of the Escherichia coli
chaperonin GroEL [PDB code 1SX3] [20], which shares 50% of
sequence identity. For building of M. leprae Hsp65 models, two
proteins were used. The atomic coordinates from the chaperonin
complex from Thermus thermophilus, chain A [37] were used for
modellingofNand Ctermini[PDBcode1WE3,residues3to70and
510 to 529, respectively] and the structural coordinates of the Hsp65
from M. tuberculosis [PDB code 1SJP, residues 60 to 514] [19]. The
bestmodelswerechosenaccordingtotheModellerobjectivefunction
and stereo chemical analyses using Procheck [52]. Angle distortions
and rotamers were corrected using COOT [53]. Secondary structure
matching [SSM] superposition of the models was obtained according
to [54]. All the figures and the electrostatic potential calculation were
obtained with ‘‘The PyMOL Molecular Graphics System’’ [55].
Alignment of Hsp60 amino acid sequences
The primary structure analysis of the mouse Hsp60 and
Mycobacterium leprae Hsp65 was performed using the Clustal W –
multiple alignment website [http://npsa-pbil.ibcp.fr], supplied
with sequences deposited in the SWISS-PROT/TrEMBL data-
base [http://expasy.org/sprot], access number: M. leprae Hsp65:
P09239; mouse Hsp60: P63038.
Major Histocompatibility Complex [MHC] class I and II
epitope binding prediction
The potential binding of the 352–371 amino acid regions of WT
and K
409A proteins to MHC class I and II was analyzed using the
RankPep tool. Theoretical recognition ratio in the consensus
sequences of each molecule of MHC class I and II and the number
of the molecules that recognize the peptides were calculated for
both proteins.
Statistical analysis
Antibody production data are expressed as the mean [X] 6
standard deviation [SD] and compared by unpaired t-test.
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test. Statistical significance was set at p,0.05.
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